In October 2021, Evaxion entered into a clinical trial collaboration and supply agreement with subsidiaries of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) to evaluate the combination of Evaxion’s cancer immunotherapy EVX-01 with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a new Phase 2b study. Under the terms of the agreement, Evaxion is responsible for conducting the study, and MSD supplies all of the necessary KEYTRUDA® and will continue to collaborate as the data matures.